{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:36:03Z","timestamp":1791920163853,"version":"4.3.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005046","name":"Natural Science Foundation of Heilongjiang Province","doi-asserted-by":"publisher","award":["No. LH2020H124"],"award-info":[{"award-number":["No. LH2020H124"]}],"id":[{"id":"10.13039\/501100005046","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2026,1,29]]},"DOI":"10.1038\/s41388-025-03584-w","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T13:08:56Z","timestamp":1764335336000},"page":"140-263","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["SLC7A5-ERBB2 axis drives olaparib resistance via de novo lipid synthesis in ovarian cancer"],"prefix":"10.1038","volume":"45","author":[{"given":"Shuang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunlong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yupeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xihai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2060-9853","authenticated-orcid":false,"given":"Rong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"3584_CR1","first-page":"280","volume":"69","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69:280\u2013304.","journal-title":"CA Cancer J Clin"},{"key":"3584_CR2","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/S1470-2045(18)30786-1","volume":"20","author":"CJ LaFargue","year":"2019","unstructured":"LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL. Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol. 2019;20:e15\u201328.","journal-title":"Lancet Oncol"},{"key":"3584_CR3","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(17)32418-2","volume":"390","author":"SD Don","year":"2017","unstructured":"Don SD. PARP inhibitors for targeted treatment in ovarian cancer. Lancet. 2017;390:1929\u201330.","journal-title":"Lancet"},{"key":"3584_CR4","first-page":"192","volume":"15","author":"L Zhang","year":"2020","unstructured":"Zhang L, Sui C, Yang W, Luo Q. Amino acid transporters: emerging roles in drug delivery for tumor-targeting therapy. Asian J Pharm Sci. 2020;15:192\u2013206.","journal-title":"Asian J Pharm Sci"},{"key":"3584_CR5","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/s41586-019-1126-2","volume":"569","author":"Y Saito","year":"2019","unstructured":"Saito Y, Li L, Coyaud E, Luna A, Sander C, Raught B, et al. LLGL2 rescues nutrient stress by promoting leucine uptake in ER+ breast cancer. Nature. 2019;569:275\u20139.","journal-title":"Nature"},{"key":"3584_CR6","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1016\/j.juro.2015.11.071","volume":"195","author":"M Xu","year":"2016","unstructured":"Xu M, Sakamoto S, Matsushima J, Kimura T, Ueda T, Mizokami A, et al. Up-regulation of LAT1 during antiandrogen therapy contributes to progression in prostate cancer cells. J Urol. 2016;195:1588\u201397.","journal-title":"J Urol"},{"key":"3584_CR7","doi-asserted-by":"publisher","first-page":"3845","DOI":"10.1038\/s41388-021-01788-4","volume":"40","author":"J Tan","year":"2021","unstructured":"Tan J, Zheng X, Li M, Ye F, Song C, Xu C, et al. C\/EBP\u03b2 promotes poly(ADP-ribose) polymerase inhibitor resistance by enhancing homologous recombination repair in high-grade serous ovarian cancer. Oncogene. 2021;40:3845\u201358.","journal-title":"Oncogene"},{"key":"3584_CR8","doi-asserted-by":"publisher","first-page":"560","DOI":"10.3390\/metabo13040560","volume":"13","author":"R Murali","year":"2023","unstructured":"Murali R, Balasubramaniam V, Srinivas S, Sundaram S, Venkatraman G, Warrier S, et al. Deregulated metabolic pathways in ovarian cancer: cause and consequence. Metabolites. 2023;13:560.","journal-title":"Metabolites"},{"key":"3584_CR9","volume":"6","author":"M Artibani","year":"2021","unstructured":"Artibani M, Masuda K, Hu Z, Rauher PC, Mallett G, Wietek N, et al. Adipocyte-like signature in ovarian cancer minimal residual disease identifies metabolic vulnerabilities of tumor-initiating cells. JCI Insight. 2021;6:e147929.","journal-title":"JCI Insight"},{"key":"3584_CR10","doi-asserted-by":"publisher","first-page":"501","DOI":"10.2147\/ITT.S479153","volume":"13","author":"H Abdel-Razeq","year":"2024","unstructured":"Abdel-Razeq H, Sharaf B, Khater S, Baidoun HJ, Bani Hani H, Taqash A, et al. Clinical outcomes of patients treated with ribociclib in combination with aromatase inhibitors or fulvestrant for HR-positive, HER2-negative metastatic breast cancer, real-world data from a low-resourced country. Immunotargets Ther. 2024;13:501\u201312.","journal-title":"Immunotargets Ther"},{"key":"3584_CR11","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1186\/s13046-021-02124-0","volume":"40","author":"C Coulson-Gilmer","year":"2021","unstructured":"Coulson-Gilmer C, Morgan RD, Nelson L, Barnes BM, Tighe A, Wardenaar R, et al. Replication catastrophe is responsible for intrinsic PAR glycohydrolase inhibitor-sensitivity in patient-derived ovarian cancer models. J Exp Clin Cancer Res. 2021;40:323.","journal-title":"J Exp Clin Cancer Res"},{"key":"3584_CR12","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1053\/j.gastro.2017.09.048","volume":"154","author":"DH Ilson","year":"2018","unstructured":"Ilson DH, van Hillegersberg R. Management of patients with adenocarcinoma or squamous cancer of the esophagus - ClinicalKey. Gastroenterology. 2018;154:437\u201351.","journal-title":"Gastroenterology"},{"key":"3584_CR13","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature14169","volume":"518","author":"N Waddell","year":"2015","unstructured":"Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518:495\u2013501.","journal-title":"Nature"},{"key":"3584_CR14","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1101\/gad.283283.116","volume":"30","author":"C Zhang","year":"2016","unstructured":"Zhang C, Liu J, Huang G, Zhao Y, Yue X, Wu H, et al. Cullin3\u2013KLHL25 ubiquitin ligase targets ACLY for degradation to inhibit lipid synthesis and tumor progression. Genes Dev. 2016;30:1956\u201370.","journal-title":"Genes Dev"},{"key":"3584_CR15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s42003-021-02958-6","volume":"5","author":"MV Sepporta","year":"2022","unstructured":"Sepporta MV, Praz V, Bourloud KB, Joseph JM, Jauquier N, Riggi N, et al. TWIST1 expression is associated with high-risk neuroblastoma and promotes primary and metastatic tumor growth. Communications Biol. 2022;5:42.","journal-title":"Communications Biol"},{"key":"3584_CR16","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13045-022-01359-4","volume":"15","author":"T Liu","year":"2022","unstructured":"Liu T, Han C, Fang P, Ma Z, Wang X, Chen H, et al. Cancer-associated fibroblast-specific lncRNA LINC01614 enhances glutamine uptake in lung adenocarcinoma. J Hematol Oncol. 2022;15:141.","journal-title":"J Hematol Oncol"},{"key":"3584_CR17","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1172\/JCI87800","volume":"127","author":"A Okazaki","year":"2017","unstructured":"Okazaki A, Gameiro PA, Christodoulou D, Laviollette L, Schneider M, Chaves F, et al. Glutaminase and poly(ADP-ribose) polymerase inhibitors suppress pyrimidine synthesis and VHL-deficient renal cancers. J Clin Investig. 2017;127:1631\u201345.","journal-title":"J Clin Investig"},{"key":"3584_CR18","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.3390\/ijms23031116","volume":"23","author":"HC Osborne","year":"2022","unstructured":"Osborne HC, Larrosa I, Schmidt CK. Sesquiterpene lactones potentiate olaparib-induced DNA damage in p53 wildtype cancer cells. Int J Mol Sci. 2022;23:1116.","journal-title":"Int J Mol Sci"},{"key":"3584_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.108767","volume":"34","author":"X Song","year":"2021","unstructured":"Song X, Liu J, Kuang F, Chen X, Zeh HJ, Kang R, et al. PDK4 dictates metabolic resistance to ferroptosis by suppressing pyruvate oxidation and fatty acid synthesis. Cell Rep. 2021;34:108767.","journal-title":"Cell Rep"},{"key":"3584_CR20","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.ccell.2019.04.002","volume":"35","author":"B Hassannia","year":"2019","unstructured":"Hassannia B, Vandenabeele P, Vanden Berghe T. Targeting ferroptosis to iron out cancer - ScienceDirect. Cancer Cell. 2019;35:830\u201349.","journal-title":"Cancer Cell"},{"key":"3584_CR21","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.canlet.2019.12.010","volume":"471","author":"P Icard","year":"2020","unstructured":"Icard P, Wu Z, Fournel L, Coquerel A, Lincet H, Alifano M. ATP citrate lyase: a central metabolic enzyme in cancer. Cancer Lett. 2020;471:125\u201334.","journal-title":"Cancer Lett"},{"key":"3584_CR22","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.tcb.2023.05.003","volume":"33","author":"LE Pope","year":"2023","unstructured":"Pope LE, Dixon SJ. Regulation of ferroptosis by lipid metabolism. Trends Cell Biol. 2023;33:1077\u201387.","journal-title":"Trends Cell Biol"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03584-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03584-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03584-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T13:47:26Z","timestamp":1766584046000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03584-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1,29]]}},"alternative-id":["3584"],"URL":"https:\/\/doi.org\/10.1038\/s41388-025-03584-w","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"23 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted in compliance with all relevant guidelines and regulations. The experimental protocol was approved by the Ethics Committee of Shanghai Superchip Biotech Co., Ltd. (Shanghai, China).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical compliance"}}]}}